UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~December~~March 227, ~~2023~~2024

Cyteir Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware	001-40499	45-5429901
(State or Other Jurisdictionof Incorporation)	(Commission File Number)	(IRS EmployerIdentification No.)
99 Hayden Street, Building B, Suite 450
P.O. Box 80084
Lexington, Massachusetts		02421
Stoneham, Massachusetts		02180
(Address of Principal Executive Offices)		(Zip Code)

    Registrant’s Telephone Number, Including Area Code: 857 285-4140

   

    Not Applicable

   

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	CYT	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 53.0201 ~~Departure~~Notice of ~~Directors~~Delisting or ~~Certain~~Failure ~~Officers;~~to ~~Election~~Satisfy ofa ~~Directors;~~Continued ~~Appointment~~Listing ofRule ~~Certain~~or ~~Officers~~Standard; ~~Compensatory~~Transfer ~~Arrangements~~ of ~~Certain Officers.~~Listing

On ~~December~~March 227, ~~2023~~2024, ~~the Compensation Committee of the Board of Directors of~~ Cyteir Therapeutics, Inc. (the "“Company"”) ~~approved~~delivered aformal ~~retention~~notice ~~program~~to ~~under~~The ~~which~~Nasdaq ~~the~~Stock ~~Company’s~~Market ~~Chief~~that ~~Executive Officer, Dr. Markus Renschler, and~~ the Company’s ~~Chief~~intends ~~Financial~~to ~~Officer,~~voluntarily ~~David~~delist ~~Gaiero,~~its ~~will~~common bestock, ~~entitled~~par tovalue a$0.001 ~~retention~~per ~~bonus~~share ~~in 2024 similar to~~ (the ~~one~~“Common ~~approved on January 17~~Stock”), ~~2023~~from ~~for~~the ~~2023,~~Nasdaq ~~and~~Global ~~reported~~Select onMarket ~~Form~~(“Nasdaq”) ~~8-K/A~~in onconnection ~~February~~with 3,the ~~2023.~~Company’s ~~The~~voluntary ~~retention~~Plan ~~bonus~~of ~~will~~Complete beLiquidation anand ~~amount~~Dissolution ~~equal~~previously toapproved ~~150%~~by of the ~~executive officer~~Company’s ~~target~~Board ~~annual~~of ~~bonus,~~Directors ~~prorated~~and ~~for the period employed during the year~~stockholders.

The Company expects to file a Notification of Removal from Listing and/or Registration on Form 25 with the Securities and Exchange Commission (the “SEC”) on or about March 18, 2024 to effect the voluntary delisting of the Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the delisting will be effective on or about March 28, 2024, ten days after the filing of the Form 25. In connection with the foregoing, the Company requested that the trading of the Common Stock on Nasdaq be suspended effective before the market opens on March 18, 2024. Following the effectiveness of the delisting, the Company intends to file a Form 15 with the SEC to terminate the registration of the Common Stock under Section 12(g) of the Exchange Act, thereby suspending the Company’s Exchange Act reporting obligations.

A copy of the press release announcing the matters summarized above is filed as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 8.01 Other Events

On March 7, 2024, the Company issued a press release regarding the matters disclosed in Item 3.01 above. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.


Exhibit No.		Description

99.1		Press Release of Cyteir Therapeutics, Inc. dated March 7, 2024
104		Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			CYTEIR THERAPEUTICS, INC.
Date:	~~December~~March 227, ~~2023~~2024	By:	/s/ David Gaiero
			Name: David GaieroTitle: Chief Financial Officer and Treasurer

Filing Compare · Cyteir Therapeutics, Inc.